Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0041

Scientific exchange · Dr. Daniel Weber

08 May 2026 · In person · Dr. Daniel Weber, Johns Hopkins · MSL James Whitfield · Vantrexa

ReviewedManualENG-0041—

Capture insight from this engagement

Location: Johns Hopkins
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Duration of response
PD-L1 testing turnaround

Scientific content used

PD-L1 testing pathway infographic
VTX core scientific deck v3.2

Questions raised

No questions recorded.

Notes

Scientific exchange with thoracic medical oncologist at Johns Hopkins. Discussed duration of response, pd-l1 testing turnaround.

Insights captured (1)

Capture insight

INS-0014Medium
Duration of response
Duration of response: recurring question reported by thoracic medical oncologist (US).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 3
Depth of exchange: 3
Actionability: 5

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0041

Audit history (0)

All create, update and approval events for this record

No audit events in sample data